UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners picked UnitedHealth Group Incorporated UNH as his final trade.

As per the recent earnings report, UnitedHealth, on Jan. 16, reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72. The company also reaffirmed its 2025 forecast.

Don't forget to check out our premarket coverage here.

Bryn Talkington of Requisite Capital Management named Energy Transfer LP ET as her final trade.

In the recent news, Energy Transfer, on Jan. 27, announced an increase in quarterly cash distribution from 32 cents to 32.50 cents per share.

Jim Lebenthal of Cerity Partners picked Vertex Pharmaceuticals Incorporated VRTX.

Adding support to his choice, the company, on Jan. 31, secured FDA approval for JOURNAVX, a non-opioid oral pain signal inhibitor for acute pain. Separately, Vertex also announced a reimbursement agreement with NHS England for CASGEVY, its CRISPR/Cas9 gene-edited therapy for sickle cell disease.

Rounding out the trades, Joe Terranova of Virtus Investment Partners named Axon Enterprise, Inc. AXON.

Supporting his view, JMP Securities analyst Trevor Walsh, on Feb. 4, maintained Axon Enterprise with a Market Outperform rating and raised the price target from $610 to $725.

Price Action:

Energy Transfer shares gained 0.1% to close at $20.79 on Wednesday.
Vertex Pharmaceuticals shares climbed 1.3% to settle at $488.44 during Wednesday's session.
UnitedHealth Group shares declined 1% to close at $539.81 on Wednesday.
Axon Enterprise shares gained 2.7% to settle at $680.52 during the session.

Check This Out: